Back to news

BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital

PR Newswire•18/11/2026•07:00 ET
1

Key Highlights

  • ➤$5.6 million upfront payment monetizes BioLineRx’s 14.4% future APHEXDA royalty interest
  • ➤GLIX1 Phase 1/2a trial currently enrolls its fourth of five planned dosing cohorts
  • ➤Proceeds will fund GLIX1 development, working capital, and partial BlackRock loan repayment
  • ➤Minimum cash balance requirement, currently $4 million, will be eliminated after partial repayment
  • ➤BioLineRx retains potential commercial milestone payments and pre-closing royalty payments

Expert Statements

Philip Serlin, Chief Executive Officer of BioLineRx

“This transaction enables us to immediately unlock the value of our APHEXDA royalty stream and strengthen our financial position while retaining the potential for future commercial milestone payments”

Philip Serlin, Chief Executive Officer of BioLineRx

“Importantly, the non-dilutive capital will provide additional financial flexibility as we continue to advance our lead development asset, GLIX1, through its ongoing Phase 1/2a clinical trial in glioblastoma and other solid tumors.”

Philip Serlin, Chief Executive Officer of BioLineRx

“We believe this transaction represents an attractive, non-dilutive financing solution for our company and our shareholders.”

Benjamin Lund, Partner at Soleus Capital

“We are pleased to partner with BioLineRx on this transaction, which provides us with an opportunity to participate in the future commercial performance of APHEXDA”

Benjamin Lund, Partner at Soleus Capital

“We believe APHEXDA represents a differentiated treatment option in stem cell mobilization for patients with multiple myeloma, and we look forward to supporting BioLineRx through this innovative financing arrangement.”

BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital PR Newswire

- Transaction provides non-dilutive capital through sale of BioLineRx's portion of future APHEXDA royalties -

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in